GNE-617 10 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
Search Results
GNE-617 5 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 2 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 1 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
Flumatinib 200 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib
Flumatinib 100 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib
Flumatinib 50 mg | Purity Not Available
TargetMol
Flumatinib is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
More Information Supplier PageFlumatinib
GNE-617 25 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
GNE-617 50 mg | 99.86%
TargetMol
GNE-617, a specific NAMPT inhibitor(IC50=5 nM), shows potency in xenograft models of cancer.
More Information Supplier PageGNE-617
WM-8014 1 mg | 99.95%
TargetMol
WM-8014 (MOZ-IN-3) is an inhibitor of MOZ(IC50=55 nM), a member of histone acetyltransferases.
More Information Supplier PageWM-8014
